GLP-1 receptor agonists in cardiometabolic and obesity research, including cardiovascular outcome trials and mechanistic studies.
Also called GLP-1, GLP-1 RA, incretin
Sources: 12 new papers · 5 key papers · updated Oct 20, 2026
“If approved to treat obstructive sleep apnea, orforglipron could be a promising oral pharmacologic option for people with overweight or obesity and this condition. A convenient daily pill may help expand access to treatment for sleep apnea, and it could potentially be used with…”
Expert labels are toward ATTAIN-OSA's result, from named public quotes (n=1). As of Nov 9, 2026.
Unverified · drafted by AI from the sources cited below
Glucagon-like peptide-1 receptor agonists are compounds that stimulate the activity of the glucagon-like peptide-1 receptor.1 Glucagon-like peptide 1 is a peptide of 36 or 37 amino acids that enhances glucose-dependent insulin release, suppresses glucagon release and gastric emptying, lowers blood glucose, and reduces food intake.2
Glucagon-like peptide-1 receptor agonists are used to treat type 2 diabetes and obesity.1 These medications are highly effective for glycaemic control, produce bodyweight reduction, and have a low risk of causing hypoglycaemia.2 Agents such as liraglutide and semaglutide, along with the dual co-agonist tirzepatide, are approved for the treatment of obesity.2 These drugs reduce risks for major adverse cardiovascular events and the risk of admission to or treatment within hospital for heart failure.2 They also reduce albuminuria and slow the decline in estimated glomerular filtration rate over time.2 A review of 21 randomized controlled trials confirmed cardiovascular benefits and evaluated safety across diverse populations.3 The beneficial cardiac effects of these antidiabetic drugs may be mediated in part by altered myocardial metabolism.4 However, a review of claims data from more than 29,000 members demonstrated a negative short-term return on investment over an 18-month time horizon due to high pharmacy costs and suboptimal adherence.5
Whether semaglutide reduces clinical heart failure events in patients with obesity-related heart failure with mildly reduced or preserved ejection fraction remains to be established.1 The exact mechanisms responsible for the positive cardiovascular effects of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes also remain to be defined.2 It is unknown whether these agents provide psychiatric benefit alongside metabolic effects in adults with schizophrenia and type 2 diabetes.3 Furthermore, while interactions involving dopamine modulation and neuroinflammatory mechanisms suggest potential benefits in alcohol use disorder, substantial gaps remain in establishing their place in therapy.4
Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults — United States, 2025
MMWR Morbidity and Mortality Weekly Report — Pierce S — Nov 2026
Evolutionary perspectives on GLP-1 receptor agonists and the modern obesity, sedentary behaviour, and loneliness epidemics
Annals of Human Biology — Knorr D — Nov 2026
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
The Lancet — Kosiborod M
346 citations · 2024 · among the most cited on GLP-1 receptor agonists
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis
Metabolism — Karakasis P
309 citations · 2024 · among the most cited on GLP-1 receptor agonists
GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits
The Lancet — Nauck M
145 citations · 2026 · among the most cited on GLP-1 receptor agonists
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists
Journal of the American College of Cardiology — Galli M
128 citations · 2025 · among the most cited on GLP-1 receptor agonists
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.
European Journal of Orthopaedic Surgery & Traumatology — Davis S — Oct 2026